S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94

Adicet Bio Stock Forecast, Price & News

+0.07 (+0.88 %)
(As of 10/15/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume85,021 shs
Average Volume134,082 shs
Market Capitalization$256.01 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ACET News and Ratings via Email

Sign-up to receive the latest news and ratings for Adicet Bio and its competitors with MarketBeat's FREE daily newsletter.

Adicet Bio logo

About Adicet Bio

Adicet Bio, Inc. is a biotechnology company, which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Trading Companies & Distributors
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$17.90 million
Book Value
$5.58 per share


Net Income
$-36.68 million




Market Cap
$256.01 million
Next Earnings Date
11/4/2021 (Estimated)


Overall MarketRank

2.17 out of 5 stars

Medical Sector

421st out of 1,361 stocks

Pharmaceutical Preparations Industry

193rd out of 668 stocks

Analyst Opinion: 3.5Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -

Adicet Bio (NASDAQ:ACET) Frequently Asked Questions

Is Adicet Bio a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adicet Bio in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Adicet Bio stock.
View analyst ratings for Adicet Bio
or view top-rated stocks.

What stocks does MarketBeat like better than Adicet Bio?

Wall Street analysts have given Adicet Bio a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Adicet Bio wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Adicet Bio?

Adicet Bio saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 461,600 shares, a decrease of 26.7% from the August 15th total of 630,100 shares. Based on an average daily trading volume, of 163,800 shares, the short-interest ratio is currently 2.8 days. Approximately 4.5% of the company's shares are sold short.
View Adicet Bio's Short Interest

When is Adicet Bio's next earnings date?

Adicet Bio is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Adicet Bio

How were Adicet Bio's earnings last quarter?

Adicet Bio, Inc. (NASDAQ:ACET) announced its quarterly earnings results on Wednesday, August, 11th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.18. The firm earned $4.81 million during the quarter, compared to the consensus estimate of $4.50 million.
View Adicet Bio's earnings history

How has Adicet Bio's stock been impacted by COVID-19?

Adicet Bio's stock was trading at $0.1345 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ACET stock has increased by 5,877.7% and is now trading at $8.04.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ACET?

7 analysts have issued 12 month price objectives for Adicet Bio's shares. Their forecasts range from $22.00 to $34.00. On average, they expect Adicet Bio's share price to reach $29.14 in the next year. This suggests a possible upside of 262.5% from the stock's current price.
View analysts' price targets for Adicet Bio
or view top-rated stocks among Wall Street analysts.

Who are Adicet Bio's key executives?

Adicet Bio's management team includes the following people:
  • Chen Schor, President, CEO, Secretary & Director (LinkedIn Profile)
  • Brian Nicholas Harvey, Chief Financial Officer
  • Francesco Galimi, Chief Medical Officer & Senior Vice President
  • Donald Healey, Chief Technology Officer
  • Blake Aftab, Vice President-Research

What other stocks do shareholders of Adicet Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adicet Bio investors own include (MRIN), FluoroPharma Medical (FPMI), Aurora Cannabis (ACB), Twitter (TWTR), QUALCOMM (QCOM), Extreme Networks (EXTR), General Electric (GE), Altria Group (MO), Sirius XM (SIRI) and Adobe (ADBE).

What is Adicet Bio's stock symbol?

Adicet Bio trades on the NASDAQ under the ticker symbol "ACET."

How do I buy shares of Adicet Bio?

Shares of ACET can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adicet Bio's stock price today?

One share of ACET stock can currently be purchased for approximately $8.04.

How much money does Adicet Bio make?

Adicet Bio has a market capitalization of $256.01 million and generates $17.90 million in revenue each year. The company earns $-36.68 million in net income (profit) each year or ($5.01) on an earnings per share basis.

How many employees does Adicet Bio have?

Adicet Bio employs 82 workers across the globe.

What is Adicet Bio's official website?

The official website for Adicet Bio is www.aceto.com.

Where are Adicet Bio's headquarters?

Adicet Bio is headquartered at 4 TRI HARBOR COURT, PORT WASHINGTON NY, 11050.

How can I contact Adicet Bio?

Adicet Bio's mailing address is 4 TRI HARBOR COURT, PORT WASHINGTON NY, 11050. The company can be reached via phone at (857) 315-5528 or via email at [email protected].

This page was last updated on 10/17/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.